Over the past 5 years, improvements in the design of antibody–drug conjugates (ADCs)
have enabled major advances that have reshaped the treatment of several advanced-stage …

Deep learning (DL) can accelerate the prediction of prognostic biomarkers from routine
pathology slides in colorectal cancer (CRC). However, current approaches rely on …

Background Mismatch repair–deficient (dMMR) tumors can be found in 10 to 15% of patients
with nonmetastatic colon cancer. In these patients, the efficacy of chemotherapy is limited …

The current standard-of-care adjuvant treatment for patients with colorectal cancer (CRC)
comprises a fluoropyrimidine (5-fluorouracil or capecitabine) as a single agent or in …

Cyclin-dependent kinase 9 (CDK9) is a member of the transcription CDK subfamily. In this
work, we preliminarily demonstrated the feasibility of CDK9 as a potent target of treatment for …

Introduction Lynch syndrome (LS) is a hereditary condition that increases the risk of
colorectal (CRC) and extracolonic cancers that exhibit microsatellite instability (MSI‐H). MSI …

Aim FOxTROT1 established a new standard of care for managing locally advanced colon
cancer (CC) with neoadjuvant chemotherapy (NAC). Six weeks of neoadjuvant oxaliplatin …

Abstract Aim The international FOxTROT trial, recently published in the Journal of Clinical
Oncology is the first randomized controlled trial testing neoadjuvant chemotherapy (NAC) …

Purpose Use of neoadjuvant chemotherapy (NAC) for locally advanced colon cancer
(LACC) remains controversial. An integrated analysis of data from high-quality studies may …

Importance Colorectal cancers (CRCs) with deficient DNA mismatch repair (dMMR) account
for 15% of all CRCs. Deficient MMR is a predictive biomarker associated with …